August 2021: Nivolumab (Opdivo, Bristol-Myers Squibb Co.) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence following rad..
Start chat
We Are Online! Chat With Us!
Scan the code
Hello,
Welcome to CancerFax !
CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.
Let us know what we can do for you.
1) Cancer treatment abroad? 2) CAR T-Cell therapy 3) Cancer vaccine 4) Online video consultation 5) Proton therapy